Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05496972 | Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology | active not recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05839600 | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | terminated | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT06386146 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | recruiting | Phase 1 / Phase 2 | 144 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT06656390 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 202 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | recruiting | Phase 2 | 450 | DualityBio Inc.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06977737 | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours(ATTEST) | recruiting | Phase 1 / Phase 2 | 72 | Accession Therapeutics LimitedINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT02321501 | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05102656 | Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic | active not recruiting | N/A | 107 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06006273 | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07167381 | xDRIVE for Florida-based Cancer Patients | recruiting | N/A | 210 | First Ascent Biomedical Inc.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07596381 | FAK Inhibitor in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 75 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07596693 | KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma) | recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05678010 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | active not recruiting | Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06400485 | AMT-676 in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 24 | Multitude Therapeutics Inc.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT06484595 | Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials(GUIDE) | completed | N/A | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06724926 | Concurrent Azeliragon With Craniospinal Irradiation | active not recruiting | Phase 1 | 21 | NYU Langone HealthOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07331155 | A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] | recruiting | Phase 2 | 110 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT07459998 | SKB103 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 277 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT07594028 | Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 126 | Sinocelltech Ltd.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 190 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05329103 | A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 65 | Peel Therapeutics IncINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT06066424 | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07224464 | The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | recruiting | N/A | 12 | New Phase Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07589530 | Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors(SOLID-NK) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia(E-STOP2) | not yet recruiting | Phase 4 | 136 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07591285 | A Study of SYS6051 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 114 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04895592 | Radiosurgery Before Surgery for the Treatment of Brain Metastases | completed | Early Phase 1 | 26 | Emory UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04960787 | Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses(CREDIT) | active not recruiting | N/A | 331 | SWOG Cancer Research NetworkNETWORK | 2 | May 14, 2026 | clinicaltrials |
| NCT06739291 | A Study of SIGX1094R in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 102 | Signet TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT07587879 | Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors(mRNA-LNP) | not yet recruiting | Phase 1 / Phase 2 | 60 | IntraAb, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07587996 | Exploratory Clinical Study of ¹⁷⁷Lu-CTR-FAPI in Patients With Metastatic Solid Tumors | completed | Early Phase 1 | 12 | Lanzhou University Second HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02797795 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | completed | Phase 1 | 78 | Neovia Oncology Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT02806388 | Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project(IMPACT) | recruiting | — | 5,500 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors(ACTengine) | recruiting | Phase 1 / Phase 2 | 375 | Immatics US, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | completed | Phase 1 / Phase 2 | 225 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 22, 2026source: clinicaltrials